Absci Corporation (ABSI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Absci Corporation (ABSI) closed at USD 8.74 on 2026-10-14, a change of +98.6 % over the past year, with a market capitalization of USD 1.52B.

Absci Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Absci Corporation key figures

Previous close

USD 8.74 (2026-10-14)

1-year change

+98.6 %

Market cap

USD 1.52B

Enterprise value

USD 1.33B

P/E ratio (trailing)

-11.53

P/E ratio (forward)

-13.15

EPS (trailing)

-0.77

EPS (forward)

-0.68

PEG ratio

n/a

Price to book

6.19

Revenue growth

-46.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.50

Employees

140

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Absci Corporation

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Absci Corporation and compare it with other stocks.